<Internation Circulation>:Will you please compare and contrast the distinctions between the factor Xa inhibitors  and the other new oral anticoagulants?

prof.Weitz:The new agents are of two types: We have oral  thrombin inhibitors and oral factor Xa inhibitors.  At ACC.10， we saw the results of some of the subgroup analyses of the phase 3 RE-LY trial with dabigatran etexilate， which is an oral thrombin inhibitor.  The drug looks very good compared with warfarin; the higher dose regimen of 150 mg twice daily produces a greater reduction in the incidence of stroke and systemic embolism than warfarin， without a significant increase in major bleeding.  Furthermore， there is less  intracranial bleeding with dabigatran than with warfarin.